Article Sidebar

PDF
Date Published: 24/02/2023
Abstract Views: 170
Views PDF: 149
DOI: https://doi.org/10.51298/vmj.v523i1.4451
Issue
Vol. 523 No. 1 (2023)
Section
Các bài báo
How to Cite
Trịnh , T. H. ., & Đỗ, H. K. . (2023). RESULTS OF THE INDUCTION CHEMOTHERAPY WITH GEMICTABINE-CISLPALTIN IN THE TREATMENT OF NASOPHARYNGEAL CARCINOMA STAGE III-IVA. Vietnam Medical Journal, 523(1). https://doi.org/10.51298/vmj.v523i1.4451

RESULTS OF THE INDUCTION CHEMOTHERAPY WITH GEMICTABINE-CISLPALTIN IN THE TREATMENT OF NASOPHARYNGEAL CARCINOMA STAGE III-IVA

Thu Hà Trịnh 1,, Hùng Kiên Đỗ2
1 Hanoi Oncology Hospital
2 National cancer hopsital

Main Article Content

Abstract

Objective: To evaluate the treatment response and toxicity profile of the induction chemotherapy with Gemcitabine-Cisplatin regimen in the treatment of patients with stage III-IVa nasopharyngeal carcinoma. Methods: A prospective descriptive study on patients who were newly diagnosed with stage III-IV nasopharyngeal carcinoma at Hanoi Oncology Hospital and National Cancer Hospital of Vietnam Vietnam from February 2020 to October 2022.The primary endpoint was response rate, and the secondary endpoints were toxicities profile of the treatment. Results: The overall response rate of the regimen was 78.3%: 18% complete response, 60.3% partial response. The common toxicities were anemia (60.2%), neutropenia (34.6%), thrombocytopenia (30.8%), vomiting, nausea (82.0%). Majority of the toxicities was grade I-II. Conclusion: Gemcitabine/cisplatin regimen in the induction chemotherapy of stage III-IV nasopharyngeal carcinoma provided a high overall response rate, well tolerance with the acceptable toxicities.

Article Details

Keywords

induction chemotherapy, Gemcitabine/cisplatin, nasopharyngeal carcinoma.

References

1. Bùi Vinh Quang. Nghiên Cứu Điều Trị Ung Thư Vòm Họng Giai Đoạn III,IV(M0) Bằng Phối Hợp Hóa Xạ Trị Gia Tốc 3 Chiều Theo Hình Dạng Khối U. Luận văn Tiến sỹ y học.Trường Đai học Y Hà Nội; 2012
2. Petit C, Lee AW, Carmel A, et al. Network-meta-analysis of chemotherapy in nasopharyngeal carcinoma (MAC-NPC): An update on 8,221 patients. J Clin Oncol. 2020;38(15_suppl):6523-6523.
3. Sun H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.
4. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019;381(12):1124-1135.
5. Zhang L, Huang Y, Hong S, et al. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2016;388(10054):1883-1892.
6. Yang Q, Cao SM, Guo L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer Oxf Engl 1990. 2019;119:87-96.